DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,798 filers reported holding DANAHER CORPORATION in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $53,823,432 | +2.6% | 217,436 | -0.5% | 13.80% | +5.9% |
| Q2 2023 | $52,456,537 | -5.8% | 218,613 | -1.1% | 13.03% | -12.8% |
| Q1 2023 | $55,688,741 | -8.3% | 220,995 | -3.4% | 14.95% | -9.8% |
| Q4 2022 | $60,703,793 | +1.0% | 228,708 | -1.7% | 16.57% | +0.3% |
| Q3 2022 | $60,115,000 | -1.3% | 232,593 | -3.2% | 16.52% | +8.9% |
| Q2 2022 | $60,930,000 | -14.0% | 240,335 | -0.5% | 15.17% | +1.6% |
| Q1 2022 | $70,822,000 | -16.5% | 241,441 | -6.4% | 14.94% | -5.2% |
| Q4 2021 | $84,834,000 | +7.4% | 257,846 | -0.7% | 15.76% | -1.7% |
| Q3 2021 | $79,000,000 | +11.9% | 259,571 | -1.4% | 16.04% | +17.1% |
| Q2 2021 | $70,630,000 | +20.6% | 263,191 | -0.6% | 13.70% | +1.4% |
| Q1 2021 | $58,572,000 | -0.9% | 264,667 | -0.4% | 13.52% | -2.6% |
| Q4 2020 | $59,093,000 | +3.2% | 265,769 | -0.0% | 13.88% | -6.7% |
| Q3 2020 | $57,247,000 | +22.8% | 265,810 | +0.8% | 14.87% | +5.8% |
| Q2 2020 | $46,637,000 | +37.6% | 263,740 | +0.2% | 14.06% | +4.5% |
| Q1 2020 | $33,896,000 | -17.7% | 263,188 | -1.9% | 13.46% | +6.2% |
| Q4 2019 | $41,194,000 | +2.6% | 268,403 | +384.1% | 12.67% | +12.0% |
| Q3 2019 | $40,133,000 | +1.2% | 55,448 | -80.0% | 11.31% | -16.6% |
| Q2 2019 | $39,647,000 | +8.5% | 277,406 | +0.2% | 13.56% | +4.0% |
| Q1 2019 | $36,547,000 | +28.8% | 276,826 | +0.6% | 13.04% | +44.5% |
| Q4 2018 | $28,371,000 | -2.3% | 275,239 | +3.0% | 9.02% | +2.1% |
| Q3 2018 | $29,027,000 | +6.3% | 267,135 | -3.4% | 8.84% | -14.3% |
| Q2 2018 | $27,296,000 | +4.0% | 276,634 | +0.9% | 10.31% | +4.1% |
| Q1 2018 | $26,241,000 | -51.1% | 274,154 | -49.9% | 9.90% | +16.3% |
| Q4 2017 | $53,620,000 | +134.4% | 547,265 | +101.6% | 8.51% | -5.0% |
| Q2 2017 | $22,873,000 | -1.0% | 271,443 | -1.2% | 8.96% | -13.2% |
| Q1 2017 | $23,095,000 | +9.3% | 274,757 | +1.2% | 10.32% | -7.7% |
| Q4 2016 | $21,128,000 | +630.3% | 271,388 | +1.7% | 11.18% | +731.4% |
| Q3 2014 | $2,893,000 | – | 266,859 | – | 1.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |